To achieve this goal, I have recruited Associate Editors for physics, chemistry/pharmacy, molecular imaging and nuclear medicine therapy and clinical nuclear imaging. Jae Sung Lee, who was the Chairman of the Scientific Committee of the Medical Imaging Conference (MIC) of the IEEE Congress 2013, took on the Associate Editorship of nuclear medicine physics; Jae Min Jeong, who was the Secretary General of the International Symposium of Radiopharmaceutical Sciences (ISRS) in 2013, took on the Associate Editorship of radiochemistry/pharmacy. Byung Chul Ahn took on the Associate Editorship of molecular imaging and Gi Jeong Cheon the Associate Editorship of nuclear medicine therapy. Won Woo Lee, Associate and Executive Editor, accepted the responsibility for the clinical nuclear medicine field along with Gi Jeong Cheon and Byung Chul Ahn. It is really delightful that Jae Min Jeong has just been elected as President-Elect of the Society of Radiopharmaceutical Sciences (SRS). This is a global representative society in the field of nuclear medicine chemistry and pharamacy.
To the Editorial Board, I invited 14 new members from abroad and 20 from my country; 14 board members stayed. Their expertise ranges from clinical nuclear medicine, nuclear medicine physics, radiochemistry, molecular imaging to basic sciences related to nuclear medicine. The Associate Editors and I are going to invite the submission of manuscripts ranging over the above disciplines as well as the already well-established case reports and interesting images. In fact, the present uniqueness of our journal Nuclear Medicine and Molecular Imaging is partly derived from the emphasis upon the importance of case and image observation in our field of nuclear medicine. I found that the globalization of the journal in terms of submissions depends mainly upon this characteristic. Now, as an incoming Editor-in-Chief, I would like to expand the scope of our journal to the areas of nuclear medicine physics, radiochemistry/pharmacy, molecular imaging and related sciences. Associate Editors and editorial members are expected to edit special issues or sections on these classical fields using their best skills to improve the authors' communications with the readers of Nuclear Medicine and Molecular Imaging. I will also invite the Editorial Board Members to contribute reviews (and visionary perspectives) regarding the existing and new fields of targeted radionuclide therapy and dosimetry; radiotheragnostics, radionanomedicine and neurodegenerative brain imaging; and inflammation theragnostics. I will also enhance the review process by inviting international referees, especially young Asian physicians and scientists. This endeavor will form the desired next-generation pool of possible authors and editors of our journal.
Realization of the globalization of this journal will soon be represented by the entitlement of the SCI(E) of our journal and by the much higher number of citations of the articles than now by the nuclear medicine community at large. I hope that the efforts made by the Associate Editors and myself will encourage continuing support from the present and new editorial board members. The extent to which we are making our journal the best evidence of the success of Koreans' collaborative efforts with each other, having different fields of expertise such as nuclear medicine physics/chemistry/ molecular-biology-based imaging and with the best young experts from the Asian continent and the rest of the world (Europe and the two American continents), will be a benchmarking achievement of our journal very soon.
I will now start my job as Editor-in-Chief by coordinating the invitation to submit review articles on the future prospects in our field, especially the possibilities and breakthroughs that have not been easily dealt with in other global journals on nuclear medicine or molecular imaging. This will have the desired and promising impact on the characteristics of our journal to emerge and become visible globally based on the prestige of the articles therein. What we need to do is just imagine the future of nuclear medicine and molecular imaging.
Let me add the importance of the development of an atmosphere of collaborative development in nuclear medicine in Asia. In the meantime, Henry Heeseung Bom, representing the Asia Oceania Foundation of Nuclear Medicine and Biology (AOFNMB) as President, has expanded AOFNMB's activities to include the Asian School of Nuclear Medicine (ASNM) and to establish the Asian Nuclear Medicine Board (ANMB) as well as launch the new journal Asia Oceania Journal of Nuclear Medicine and Biology (AOJNMB). The AOFNMB leadership is now trying to include the new Arabic Asian Society of Nuclear Medicine (Arasia SNM) as an active participant. Asian experts in nuclear medicine and the related sciences now have various choices for publishing their own research results in Annals of Nuclear Medicine, Asia Oceania Journal of Nuclear Medicine and Nuclear Medicine and Molecular Imaging. I envision that our journal Nuclear Medicine and Molecular Imaging will contribute to the Korean success in developing and achieving the global goals of research and practice of basic and clinical nuclear medicine in association with global colleagues and contribute to visualizing the expansive nature of our specialty.
Our dear readers, colleagues and peers can expect much further progress of our journal to the next level of scientific and medical progress in nuclear medicine.
